0 184

Cited 36 times in

Pulmonary marginal zone B-cell lymphoma of MALT type--what is a prognostic factor and which is the optimal treatment, operation, or chemotherapy?: Consortium for Improving Survival of Lymphoma (CISL) study

DC FieldValueLanguage
dc.contributor.author김진석-
dc.date.accessioned2015-04-23T17:15:23Z-
dc.date.available2015-04-23T17:15:23Z-
dc.date.issued2010-
dc.identifier.issn0939-5555-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/102117-
dc.description.abstractPulmonary marginal zone B-cell lymphoma of the MALT type (P-MZL) is a relatively rare form of lymphoma. We conducted a retrospective analysis of the clinical features and treatment outcomes of P-MZL for the evaluation of prognostic factors, and to collect information about the optimal treatment modality for this condition. From 1991 to 2008, a total of 61 patients with biopsy-confirmed P-MZL were retrospectively analyzed. The median age of our subjects was 60 (range, 34-79) years. Twenty-five of the patients (41%) were initially diagnosed without any symptoms. Video-assisted thoracic surgery was utilized for diagnosis in 19 patients (31%). Thirty-eight patients' conditions (62%) involved a single lobe. Lung lesions were bilateral in 15 patients (25%). Eleven patients evidenced synchronous involvement of extra-pulmonary site MZL. Overall, 56 of 61 patients were treated with surgery (n = 22), chemotherapy (n = 28), or radiotherapy (n = 6). Among them, 46 patients achieved complete or partial remission. The median time to progression (TTP) was 5.6 (95% CI, 2.6-8.6) years. Five patients died during follow-up. Extra-pulmonary MZL and LN involvement were shown to be poor prognostic factors for TTP. We noted no differences between the operation group and chemotherapy group in terms of TTP. P-MZL tends to be an indolent disease-characterized by prolonged survival with frequent relapses. This is similar to what is observed with other cases of MALT-type site MZL. In order to conserve lung function and reduce the risks of operation, chemotherapy should be considered as a first-line option for the treatment of P-MZL.-
dc.description.statementOfResponsibilityopen-
dc.format.extent563~568-
dc.relation.isPartOfANNALS OF HEMATOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHAntineoplastic Combined Chemotherapy Protocols/therapeutic use*-
dc.subject.MESHDiagnostic Techniques, Respiratory System-
dc.subject.MESHDisease Progression-
dc.subject.MESHFemale-
dc.subject.MESHHumans-
dc.subject.MESHLung Neoplasms/diagnosis*-
dc.subject.MESHLung Neoplasms/mortality-
dc.subject.MESHLung Neoplasms/therapy*-
dc.subject.MESHLymphoma, B-Cell, Marginal Zone/diagnosis*-
dc.subject.MESHLymphoma, B-Cell, Marginal Zone/mortality-
dc.subject.MESHLymphoma, B-Cell, Marginal Zone/therapy*-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHPrognosis-
dc.subject.MESHRetrospective Studies-
dc.subject.MESHSurvival Analysis-
dc.subject.MESHThoracic Surgery, Video-Assisted/utilization-
dc.subject.MESHTomography, X-Ray Computed-
dc.subject.MESHTreatment Outcome-
dc.titlePulmonary marginal zone B-cell lymphoma of MALT type--what is a prognostic factor and which is the optimal treatment, operation, or chemotherapy?: Consortium for Improving Survival of Lymphoma (CISL) study-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학)-
dc.contributor.googleauthorSung Yong Oh-
dc.contributor.googleauthorWon Seog Kim-
dc.contributor.googleauthorJin Seok Kim-
dc.contributor.googleauthorSeok Jin Kim-
dc.contributor.googleauthorHyuk-Chan Kwon-
dc.contributor.googleauthorDae Ho Lee-
dc.contributor.googleauthorJong Ho Won-
dc.contributor.googleauthorIn Gyu Hwang-
dc.contributor.googleauthorMin Kyoung Kim-
dc.contributor.googleauthorSoon Il Lee-
dc.contributor.googleauthorYee Soo Chae-
dc.contributor.googleauthorDeok-Hwan Yang-
dc.contributor.googleauthorGyeong-Won Lee-
dc.contributor.googleauthorChul Won Choi-
dc.contributor.googleauthorJinny Park-
dc.contributor.googleauthorCheolwon Suh-
dc.contributor.googleauthorHyo-Jin Kim-
dc.identifier.doi10.1007/s00277-009-0875-7-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA01017-
dc.relation.journalcodeJ00161-
dc.identifier.eissn1432-0584-
dc.identifier.pmid20024551-
dc.identifier.urlhttp://link.springer.com/article/10.1007%2Fs00277-009-0875-7-
dc.contributor.alternativeNameKim, Jin Seok-
dc.contributor.affiliatedAuthorKim, Jin Seok-
dc.citation.volume89-
dc.citation.number6-
dc.citation.startPage563-
dc.citation.endPage568-
dc.identifier.bibliographicCitationANNALS OF HEMATOLOGY, Vol.89(6) : 563-568, 2010-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.